|Dr. Mitchell S. Steiner M.D., F.A.C.S||Chairman, Pres & CEO||509.05k||N/A||1961|
|Dr. Harry Fisch||Vice Chairman & Chief Corp. Officer||217.4k||N/A||1959|
|Ms. Michele Greco||CFO, Exec. VP of Fin. & Chief Admin. Officer||360.9k||N/A||1959|
|Dr. K. Gary Barnette Ph.D.||Chief Scientific Officer||76.12k||N/A||1968|
|Philip Greenberg||Exec. VP of Legal & Sec.||N/A||N/A||N/A|
Veru Inc., an oncology and urology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care, and urology specialty pharmaceuticals. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST* 4% benzocaine WIPES for the prevention of premature ejaculation. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist, planned Phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN*, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its customers primarily include international agencies, non-government organizations, and ministries of health and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida with offices in London, United Kingdom and Kuala Lumpur, Malaysia.
Veru Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.